The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial
Journal of Affective Disorders · 2025
DOI: 10.1016/j.jad.2024.09.129 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Ying-Chih Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, China Medical University Hsinchu Hospital, China Medical University, Hsinchu, Taiwan; Institute of Epidemiology and Prevent…. Hauptthemen laut MEDLINE: Fatty Acids, Omega-3, Dietary Supplements. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Taiwan Institute of Technology, Ministry of Science and Technology, Taiwan, Taipei City Hospital.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Reports on the efficacy of omega-3 fatty acids (n-3 PUFAs) for the treatment of late-life depression (LLD) are mixed, and most studies focus on the modification of depressive symptoms rather than depression prevention. The aim of the present study was to investigate the efficacy of n-3 PUFAs in preventing depressive recurrence in patients with late-life depression. In addition, we investigated the effects of n-3 PUFAs on changes in depressive and anxiety symptoms and inflammatory markers in LLD. METHODS: A 52-week, double-blind, randomized, controlled trial was conducted. We enrolled a total of 39 euthymic patients with LLD. They were randomized to receive either n-3 PUFAs (1.2 g per day of eicosapentaenoic acid and 1 g of docosahexaenoic acid) or placebo for 52 weeks. Recurrence of depression and severity of depression symptoms were assessed at baseline and weeks 4, 8, 16, 24, 32, 40, and 52. RESULTS: A total of 39 patients completed the trial with 19 in the n-3 PUFAs group and 20 in the placebo group. Cox proportional hazard regression indicated that n-3 PUFAs had significant protective effect on depression recurrence (Hazard Ratio: 0.295, 95 % Confidence Interval: 0.093-0.931, p value =0.037). But n-3 PUFAs intervention had no significant effect in reducing depressive or anxiety symptoms, inflammatory markers over the placebo group. LIMITATION: The results should be interpreted with consideration of the modest sample size. CONCLUSION: These findings suggest that n-3 PUFAs may have a prophylactic effect in currently euthymic patients with LLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, China Medical University Hsinchu Hospital, China Medical University, Hsinchu, Taiwan; Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Ta…
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Songde Branch, Tai…
- College of Medicine, Chang Gung University, Taoyuan County, Taiwan; Department of Psychiatry, Keelung Chang Gung Memorial Hospital, Keelung City, Taiwan; Community Medicine Research Center, Chang Gung Memorial Hospital,…
- College of Medicine, Chang Gung University, Taoyuan County, Taiwan; Department of Psychiatry, Linkou Chang Gung Memorial Hospital, Taoyuan County, Taiwan.
- Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Songde Branch, Taiwan; Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. Electr…
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan; Department of Publi…
Förderung
- National Taiwan Institute of Technology
- Ministry of Science and Technology, Taiwan
- Taipei City Hospital
- Taipei City Government
- Chang Gung Memorial Hospital
Zitieren
APA
Cheng, Y. C., Chen, W. Y., Lin, C., Lee, S. H., Chiu, C. C., & Kuo, P. H. (2025). The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.09.129
Vancouver
Cheng YC, Chen WY, Lin C, Lee SH, Chiu CC, Kuo PH. The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2024.09.129
BibTeX
@article{Cheng2025,
author = {Cheng, Ying-Chih and Chen, Wen-Yin and Lin, Chemin and Lee, Shwu-Hua and Chiu, Chih-Chiang and Kuo, Po-Hsiu},
title = {The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial},
journal = {Journal of Affective Disorders},
year = {2025},
doi = {10.1016/j.jad.2024.09.129}
}
EUVIMED